Methods to induce labour: a systematic review, network meta-analysis and cost-effectiveness analysis

作者：Alfirevic Z^*; Keeney E; Dowswell T; Welton N J; Medley N; Dias S; Jones L V; Caldwell D M

来源：BJOG: An International Journal of Obstetrics and Gynaecology , 2016, 123(9): 1462-1470.

DOI：10.1111/1471-0528.13981

• Comparative effectiveness research
• cost-effectiveness analysis
• labour induction
• network meta-analysis
• systematic review

Objectives To compare the clinical effectiveness and cost-effectiveness of labour induction methods.
Methods We conducted a systematic review of randomised trials comparing interventions for third-trimester labour induction (search date: March 2014). Network meta-analysis was possible for six of nine prespecified key outcomes: vaginal delivery within 24 hours (VD24), caesarean section, uterine hyperstimulation, neonatal intensive care unit (NICU) admissions, instrumental delivery and infant Apgar scores. We developed a decision-tree model from a UK NHS perspective and calculated incremental cost-effectiveness ratios, expected costs, utilities and net benefit, and cost-effectiveness acceptability curves.
Main results In all, 611 studies comparing 31 active interventions were included. Intravenous oxytocin with amniotomy and vaginal misoprostol (>= 50 mu g) were most likely to achieve VD24. Titrated low-dose oral misoprostol achieved the lowest odds of caesarean section, but there was considerable uncertainty in ranking estimates. Vaginal (>= 50 mu g) and buccal/sublingual misoprostol were most likely to increase uterine hyperstimulation with high uncertainty in ranking estimates. Compared with placebo, extra-amniotic prostaglandin E-2 reduced NICU admissions. There were insufficient data to conduct analyses for maternal and neonatal mortality and serious morbidity or maternal satisfaction.
Conclusions were robust after exclusion of studies at high risk of bias. Due to poor reporting of VD24, the cost-effectiveness analysis compared a subset of 20 interventions. There was considerable uncertainty in estimates, but buccal/sublingual and titrated (low-dose) misoprostol showed the highest probability of being most cost-effective. Conclusions Future trials should be designed and powered to detect a method that is more cost-effective than low-dose titrated oral misoprostol.

• 出版日期2016-8